BOSTON, April 7, 2014 /CNW/ - Piramal Enterprises' Pharma Solutions Division, a global pharmaceutical contract development and manufacturing organization (CDMO), has received CMO Leadership Awards 2013 in two categories - Quality and Reliability, at a prestigious ceremony at DCAT in New York. Within the Reliability category, Piramal has been recognized as the most "Reliable" CMO among the 5 CMOs shortlisted for this award.
The CMO Leadership Awards are given by Life Science Leader based on the industry-leading research conducted by Nice Insight. They survey over 11,000 buyers of outsourced services annually to determine perception and awareness scores of CMOs for five different attributes (i.e. Innovation, Productivity, Quality, Regulatory, and Reliability). Companies achieving top 20 percentile perception scores across these 5 attributes are recognized for their achievement.
The annual award recognizes those contract manufacturing organizations (CMOs) that are the most highly rated by industry respondents. Unlike other industry awards, which are given based on a subjective voting or nomination process, the only votes that count towards the CRO/CMO Leadership Awards are those of the pharmaceutical and biopharmaceutical companies using CRO/CMO services.
Mr. Vivek Sharma, CEO - Pharma Solutions & Critical Care Division, Piramal Enterprises Ltd said, "These awards are a representation of our work which all our sites have been implementing for our customers. This recognition is a huge achievement for us and a step forward in our mission to move towards "Customer Centricity". Being Customer Centric is not just about asking what the customer wants, it is about reading signs, pre-empting expectations and going beyond what is an obvious choice."
Piramal Pharma Solutions is known for its capabilities as an integrated solutions provider, offering a comprehensive range of services across the drug lifecycle. It has a successful performance record of over 40 years for the supply of APIs and Drug Products and Drug Discovery services to the US and European markets from its facilities located in North America, Europe and India. Niche technologies such as Biocatalysis & Advanced Flow Reactors (AFR) are an area of focus to support our customers to develop cost-competitive processes.
Significant investments in new technologies and capacity expansions have been made recently such as upgrading the US FDA approved Grangemouth, UK, ADC manufacturing facility with an investment of USD 2.5 million. Furthermore, Piramal is investing 11 million USD at its Morpeth, UK facility to triple the production capacity for hormonal products.
About Piramal Enterprises Ltd:
Piramal Enterprises (PEL) is one of India's largest diversified companies, with a presence in pharmaceuticals, financial services and healthcare information management sectors. PEL had consolidated revenues of over $650 million in FY2013. In the pharmaceutical space, PEL is one of the leading Contract Development and Manufacturing organizations globally, and has a strong presence in the global critical care segment with a portfolio of inhalation and injectable anesthetics. Its OTC business is ranked no. 7 in India. PEL is also engaged in drug discovery and research, and has a strong pipeline of development products. In the financial services space, PEL has a real estate focused PE fund - Indiareit, and a NBFC that is focused on lending to the real estate and education sectors. PEL's healthcare information management business, Decision Resources Group, is a leading provider of information-based services to the healthcare industry.
SOURCE: Piramal Enterprises Ltd.
For further information: For Media Queries: Akansha Pradhan / Riddhi Goradia, Corporate Communications, Piramal Group, Contact: +91-22-3351-4082/4083, email@example.com, firstname.lastname@example.org